BIB vs. XBI
Compare and contrast key facts about ProShares Ultra Nasdaq Biotechnology (BIB) and SPDR S&P Biotech ETF (XBI).
BIB and XBI are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. BIB is a passively managed fund by ProShares that tracks the performance of the NASDAQ Biotechnology Index (200%). It was launched on Apr 7, 2010. XBI is a passively managed fund by State Street that tracks the performance of the S&P Biotechnology Select Industry Index. It was launched on Feb 6, 2006. Both BIB and XBI are passive ETFs, meaning that they are not actively managed but aim to replicate the performance of the underlying index as closely as possible.
Performance
BIB vs. XBI - Performance Comparison
Loading graphics...
BIB vs. XBI - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
BIB ProShares Ultra Nasdaq Biotechnology | 3.51% | 59.21% | -9.84% | -1.06% | -28.85% | -6.02% | 39.79% | 46.71% | -24.93% | 40.49% |
XBI SPDR S&P Biotech ETF | 5.43% | 35.89% | 1.01% | 7.60% | -25.87% | -20.45% | 48.33% | 32.56% | -15.28% | 43.77% |
Returns By Period
In the year-to-date period, BIB achieves a 3.51% return, which is significantly lower than XBI's 5.43% return. Over the past 10 years, BIB has underperformed XBI with an annualized return of 6.98%, while XBI has yielded a comparatively higher 9.39% annualized return.
BIB
- 1D
- 1.31%
- 1M
- -5.43%
- YTD
- 3.51%
- 6M
- 32.05%
- 1Y
- 82.75%
- 3Y*
- 16.12%
- 5Y*
- 0.02%
- 10Y*
- 6.98%
XBI
- 1D
- 0.64%
- 1M
- 1.58%
- YTD
- 5.43%
- 6M
- 27.21%
- 1Y
- 65.07%
- 3Y*
- 19.25%
- 5Y*
- -1.16%
- 10Y*
- 9.39%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
BIB vs. XBI - Expense Ratio Comparison
BIB has a 0.95% expense ratio, which is higher than XBI's 0.35% expense ratio.
Return for Risk
BIB vs. XBI — Risk / Return Rank
BIB
XBI
BIB vs. XBI - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for ProShares Ultra Nasdaq Biotechnology (BIB) and SPDR S&P Biotech ETF (XBI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| BIB | XBI | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 1.78 | 2.28 | -0.50 |
Sortino ratioReturn per unit of downside risk | 2.29 | 2.99 | -0.70 |
Omega ratioGain probability vs. loss probability | 1.29 | 1.38 | -0.09 |
Calmar ratioReturn relative to maximum drawdown | 3.35 | 4.41 | -1.06 |
Martin ratioReturn relative to average drawdown | 11.88 | 16.21 | -4.33 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| BIB | XBI | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.78 | 2.28 | -0.50 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.00 | -0.04 | +0.04 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.15 | 0.29 | -0.14 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.35 | 0.36 | -0.01 |
Correlation
The correlation between BIB and XBI is 0.91, which is considered to be high. That indicates a strong positive relationship between their price movements. Having highly-correlated positions in a portfolio may signal a lack of diversification, potentially leading to increased risk during market downturns.
Dividends
BIB vs. XBI - Dividend Comparison
BIB's dividend yield for the trailing twelve months is around 0.60%, more than XBI's 0.34% yield.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
BIB ProShares Ultra Nasdaq Biotechnology | 0.60% | 0.77% | 1.69% | 0.07% | 0.03% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
XBI SPDR S&P Biotech ETF | 0.34% | 0.37% | 0.15% | 0.02% | 0.00% | 0.04% | 0.20% | 0.00% | 0.28% | 0.24% | 0.26% | 0.61% |
Drawdowns
BIB vs. XBI - Drawdown Comparison
The maximum BIB drawdown since its inception was -67.24%, which is greater than XBI's maximum drawdown of -63.89%. Use the drawdown chart below to compare losses from any high point for BIB and XBI.
Loading graphics...
Drawdown Indicators
| BIB | XBI | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -67.24% | -63.89% | -3.35% |
Max Drawdown (1Y)Largest decline over 1 year | -21.73% | -13.39% | -8.34% |
Max Drawdown (5Y)Largest decline over 5 years | -65.86% | -55.04% | -10.82% |
Max Drawdown (10Y)Largest decline over 10 years | -66.20% | -63.89% | -2.31% |
Current DrawdownCurrent decline from peak | -23.89% | -25.70% | +1.81% |
Average DrawdownAverage peak-to-trough decline | -32.84% | -20.91% | -11.93% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 6.13% | 3.65% | +2.48% |
Volatility
BIB vs. XBI - Volatility Comparison
ProShares Ultra Nasdaq Biotechnology (BIB) has a higher volatility of 16.73% compared to SPDR S&P Biotech ETF (XBI) at 11.31%. This indicates that BIB's price experiences larger fluctuations and is considered to be riskier than XBI based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| BIB | XBI | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 16.73% | 11.31% | +5.42% |
Volatility (6M)Calculated over the trailing 6-month period | 28.82% | 19.25% | +9.57% |
Volatility (1Y)Calculated over the trailing 1-year period | 47.20% | 28.95% | +18.25% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 43.32% | 32.23% | +11.09% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 46.77% | 32.15% | +14.62% |